Comparison of risk stratification of ER-positive, node-negative breast cancer patients by Oncotype DX versus molecular grade index and HOXB13/IL17BR ratio

被引：0
|
作者：
Sgroi, D.
Hameed, O.
Hattab, E.
Chang, B.
Moulis, S.
Steffel, L.
Salunga, R.
Ma, X.
Erlander, M.
Goss, P.
机构：
[1] Harvard Univ, Sch Med, Massachussets Gen Hosp, Charlestown, MA USA
[2] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA
[3] Indiana Univ, Indianapolis, IN 46204 USA
[4] Scripps Mem Hosp, La Jolla, CA USA
[5] AviaraDx, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.22061
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
22061
引用
收藏
页数：1
相关论文
共 43 条
  • [21] Correlative studies of the breast cancer index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine benefit: A trans-aTTom study
    Sgroi, Dennis C.
    Treuner, Kai
    Zhang, Yi
    Piper, Tammy
    Salunga, Ranelle
    Ahmed, Ikhlaaq
    Doos, Lucy
    Thornber, Sarah
    Taylor, Karen J.
    Brachtel, Elena F.
    Pirrie, Sarah
    Schnabel, Catherine A.
    Rea, Daniel W.
    Bartlett, John M. S.
    CANCER RESEARCH, 2021, 81 (04)
  • [22] Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study
    Dennis C. Sgroi
    Kai Treuner
    Yi Zhang
    Tammy Piper
    Ranelle Salunga
    Ikhlaaq Ahmed
    Lucy Doos
    Sarah Thornber
    Karen J. Taylor
    Elena Brachtel
    Sarah Pirrie
    Catherine A. Schnabel
    Daniel Rea
    John M. S. Bartlett
    Breast Cancer Research, 24
  • [23] Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study
    Sgroi, Dennis C. C.
    Treuner, Kai
    Zhang, Yi
    Piper, Tammy
    Salunga, Ranelle
    Ahmed, Ikhlaaq
    Doos, Lucy
    Thornber, Sarah
    Taylor, Karen J. J.
    Brachtel, Elena
    Pirrie, Sarah
    Schnabel, Catherine A. A.
    Rea, Daniel
    Bartlett, John M. S.
    BREAST CANCER RESEARCH, 2022, 24 (01)
  • [24] Correlation of breast cancer index (BCI) predictive (HoxB13/IL17BR) results to nodal status and hormone receptor expression in early stage HR plus breast cancer
    Elias, Anthony
    Israel, Mason A.
    Zhang, Yi
    Schnabel, Catherine A.
    Mayordomo, Jose
    CANCER RESEARCH, 2018, 78 (04)
  • [25] A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK
    Holt, S.
    Bertelli, G.
    Humphreys, I.
    Valentine, W.
    Durrani, S.
    Pudney, D.
    Rolles, M.
    Moe, M.
    Khawaja, S.
    Sharaiha, Y.
    Brinkworth, E.
    Whelan, S.
    Jones, S.
    Bennett, H.
    Phillips, C. J.
    BRITISH JOURNAL OF CANCER, 2013, 108 (11) : 2250 - 2258
  • [26] A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK
    S Holt
    G Bertelli
    I Humphreys
    W Valentine
    S Durrani
    D Pudney
    M Rolles
    M Moe
    S Khawaja
    Y Sharaiha
    E Brinkworth
    S Whelan
    S Jones
    H Bennett
    C J Phillips
    British Journal of Cancer, 2013, 108 : 2250 - 2258
  • [27] Prediction of benefit from endocrine therapy in ER plus early stage breast cancer: Correlative studies of the breast cancer index HoxB13/IL17BR (H/I) ratio, ER, PR, and HER2 expression in the randomized Stockholm trial
    Zhang, Yi
    Schroeder, Brock E.
    Jannok, Piiha-Lotta Jerevall
    Fornander, Tommy
    Stal, Olle
    Schnabel, Catherine A.
    Sgroi, Dennis C.
    CANCER RESEARCH, 2015, 75
  • [28] Correlation of Breast Cancer Index HOXB13/IL17BR (H/I), ER, PR and HER2 and prediction of relative endocrine benefit from tamoxifen and anastrozole in HR plus breast cancer: A TransATAC study.
    Zhang, Yi
    Sestak, Ivana
    Cuzick, Jack M.
    Dowsett, Mitchell
    Schnabel, Catherine A.
    Sgroi, Dennis
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial.
    Goetz, M.
    Ames, M.
    Gnant, M.
    Filpits, M.
    Jakesz, R.
    Greil, R.
    Marth, C.
    Samonigg, H.
    Suman, V
    Safgren, S.
    Kuffel, M.
    Weinshilboum, R.
    Erlander, M.
    Ma, X.-J.
    Ingle, J.
    CANCER RESEARCH, 2009, 69 (02) : 77S - 77S
  • [30] Gene expression patterns in younger versus older HR plus breast cancer patients: An age-related analysis of HoxB13/IL17BR (H/I), proliferation status, and quantitative hormone receptor expression
    Melisko, Michelle
    Chien, A. Jo
    Poage, Graham M.
    Salganik, Max
    Schnabel, Catherine A.
    Ruddy, Kathryn J.
    Blackwell, Kimberly
    CANCER RESEARCH, 2018, 78 (04)
12345